1. Search Result
Search Result
Results for "

hypoglycemic

" in MCE Product Catalog:

37

Inhibitors & Agonists

13

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-130003
    Hypoglycemic agent 1

    Others Metabolic Disease
    Hypoglycemic agent 1 acts as a therapeutic and/or prophylactic agent for diabetes. Hypoglycemic agent 1 has an action for lowering blood sugar.
  • HY-N7910
    Stachyose

    Endogenous Metabolite Metabolic Disease
    Stachyose, a kind of oligosaccharides, act as a hypoglycemic agent.
  • HY-135670B
    Glycosidase-IN-2

    Others Metabolic Disease
    Glycosidase-IN-2 (Compound 20) is an azasugar class of glycosidase inhibitor. Glycosidase-IN-2 has hypoglycemic activity.
  • HY-15383
    Glyparamide

    Others Others
    Glyparamide is an orally active chlorophenyl-containing sulfonylurea. Glyparamide shows hypoglycemic activity and rarely causes hepatic injury.
  • HY-W011651
    Carbutamide

    BZ-55

    Others Metabolic Disease
    Carbutamide (BZ-55) is an orally active and first-generation sulfonylurea with hypoglycemic activity.
  • HY-135670A
    β-glycosidase-IN-1

    Others Metabolic Disease
    β-glycosidase-IN-1 (Compound 33) is a piperidine derivative and a β-glycosidase inhibitor. β-glycosidase-IN-1 has hypoglycemic activity.
  • HY-N7377
    Butyl isobutyl phthalate

    Glucosidase Metabolic Disease
    Butyl isobutyl phthalate is isolated from the rhizoid of Laminaria japonica. Butyl isobutyl phthalate is a non-competitive α-glucosidase inhibitor with an IC50 value of 38 μM. Butyl isobutyl phthalate shows a hypoglycemic effect and has the potential for diabetes treatment.
  • HY-N4147
    Eleutheroside D

    Others Metabolic Disease Inflammation/Immunology
    Eleutheroside D is an active lignan isolated from the root of Eleutherococcus senticosus, has anti-inflammatory and hypoglycemic activities. Eleutheroside D is an optical isomer of Eleutheroside E (HY-N0272).
  • HY-121565
    SaRI 59-801

    Others Endocrinology Metabolic Disease
    SaRI 59-801 is an orally effective hypoglycemic compound. SaRI 59-801 decreases blood glucose in several species and to elevate plasma insulin in rats and mice.
  • HY-135670
    Glycosidase-IN-1

    Others Metabolic Disease
    Glycosidase-IN-1 (Compound 9) is a glycosidase inhibitor synthesized from D-mannose. Glycosidase-IN-1 be used to synthesize some immunosuppressive agents and β-glucosidase inhibitors. Glycosidase-IN-1 has hypoglycemic activity.
  • HY-N0820
    Catalpol

    Catalpinoside

    HBV Cancer Infection Inflammation/Immunology Neurological Disease
    Catalpol (Catalpinoside), an iridoid glycoside found in Rehmannia glutinosa. Catalpol has neuroprotective, hypoglycemic, anti-inflammatory, anti-cancer, anti-spasmodic, anti-oxidant effects and anti-HBV effects.
  • HY-N5086
    Picroside IV

    Others Infection Metabolic Disease Inflammation/Immunology Neurological Disease
    Picroside IV is an iridoid glycoside found in the underground parts of Picrorhiza scrophulariiflora. Picroside IV is a derivative of Catalpol (HY-N0820). Catalpol has neuroprotective, hypoglycemic, anti-inflammatory, anti-cancer, anti-spasmodic, anti-oxidant effects and anti-HBV effects.
  • HY-W011220
    Ciglitazone

    ADD-3878; U-63287

    PPAR Cancer Cardiovascular Disease
    Ciglitazone is a potent and selective PPARγ agonist (EC50=3 μM). Ciglitazone inhibits proliferation and differentiation of th17 cells. Ciglitazone is a hypoglycemic agent orally active in the obese-hyperglycemic animal models. Ciglitazone induces apoptosis accompanied by activation of p38 MAPK and nuclear translocation of apoptosis inducing factor (AIF) in opossum kidney (OK) renal epithelial cells.
  • HY-150723
    PBI-6DNJ

    Glucosidase Metabolic Disease
    PBI-6DNJ is an orally active and potent multivalent glycosidase inhibitor. PBI-6DNJ exhibits good inhibition activity against α-glucosidase from mice, with a Ki of 0.14 μM. PBI-6DNJ exhibits good hypoglycemic activity. PBI-6DNJ can be used for type 2 diabetes research.
  • HY-U00012
    Glyhexamide

    SQ 15860; Serbose; Subose

    Others Metabolic Disease
    Glyhexamide is an effective hypoglycemic agent in adult diabetics.
  • HY-B1103
    Hydroxyhexamide

    (±)-Hydroxyhexamid

    Drug Metabolite Cardiovascular Disease
    Hydroxyhexamide is a pharmacologically active metabolite of Acetohexamide, used as a hypoglycemic agents.
  • HY-B0401
    Tolbutamide

    Potassium Channel Autophagy Metabolic Disease Cancer
    Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic drug.
  • HY-N9725
    16-Hydroxycleroda-3,13-dien-15,16-olide

    16ξ-Hydroxycleroda-3,13-dien-15,16-olide

    Dipeptidyl Peptidase Metabolic Disease
    16-Hydroxycleroda-3,13-dien-15,16-olide (16ξ-Hydroxycleroda-3,13-dien-15,16-olide; HCD), a clerodane diterpene, is a potent serine protease dipeptidyl peptidase 4 (DPP-4) inhibitor. 16-Hydroxycleroda-3,13-dien-15,16-olide down-regulates LPS-induced ERK phosphorylation in myocyte but blocks GLP-1 induced PKA expression. 16-Hydroxycleroda-3,13-dien-15,16-olide exhibits hypolipidemic, hepatoprotective, hypoglycemic efficacy.
  • HY-B0401S
    Tolbutamide-d9

    Potassium Channel Autophagy Metabolic Disease Cancer
    Tolbutamide-d9 is the deuterium labeled Tolbutamide. Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic drug.
  • HY-N0661
    Alliin

    Others Inflammation/Immunology Cardiovascular Disease
    Alliin, an orally active sulfoxide compound derived from garlic, exhibits hypoglycemic, antioxidant and anti-inflammatory activities.
  • HY-B0401S1
    Tolbutamide-13C

    Potassium Channel Autophagy Metabolic Disease Cancer
    Tolbutamide-13C is the 13C-labeled Tolbutamide. Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic drug.
  • HY-N0299
    Stachyose hydrate

    Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    Stachyose hydrate act as a prebiotic to enhance the growth and activity of beneficial bacteria. Stachyose hydrate exhibit a hypoglycemic effect, and improve inflammation through modulating gut microbiota.
  • HY-N0205
    Pulchinenoside C

    Anemoside B4

    Others Cancer
    Pulchinenoside C (Anemoside B4) is Pulsatilla koreana Nakai that have many numerous biological effects in vitro, including enhancing hypoglycemic, anti-tumor, neuroprotective and anti-angiogenic activity.
  • HY-B0089
    Acarbose

    BAY g 5421

    Glucosidase Metabolic Disease
    Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin.
  • HY-B0089A
    Acarbose sulfate

    Bay-g 5421 sulfate

    Glucosidase Metabolic Disease
    Acarbose (BAY g 5421) sulfate, antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose sulfate can potentiate the hypoglycemic effects of sulfonylureas or insulin.
  • HY-N2000
    Bellidifolin

    HIV Cancer Infection Inflammation/Immunology
    Bellidifolin is a xanthone isolated from the stems of Swertia punicea, with hepatoprotective, hypoglycemic, anti-oxidation, anti-inflammatory and antitumor activities. Bellidifolin also acts as a viral protein R (Vpr) inhibitor.
  • HY-N2229
    Rhapontigenin

    Cytochrome P450 Fungal Bacterial Cancer Infection Inflammation/Immunology
    Rhapontigenin is a natural analog of resveratrol with anticancer, antioxidant, antifungal and antibacterial activities. Rhapontigenin is amechanism-based, potent and selective cytochrome P450 1A1 inactivator (IC50  = 400 nM). Rhapontigenin exhibits 400-fold and 23-fold selectivity for P450 1A1 over P450 1A2 and P450 1B1, respectively.
  • HY-N0655
    D-Pinitol

    3-O-Methyl-D-chiro-inositol

    Influenza Virus Infection Inflammation/Immunology Cardiovascular Disease
    D-pinitol (3-O-Methyl-D-chiro-inositol) is a natural compound presented in several plants, like Pinaceae and Leguminosae plants. D-pinitol exerts hypoglycemic activity and protective effects in the cardiovascular system. D-pinitol has antiviral and larvicidal activities.
  • HY-128923
    SKF-34288 hydrochloride

    3-Mercaptopicolinic acid hydrochloride

    Others Metabolic Disease
    SKF-34288 hydrochloride (3-Mercaptopicolinic acid) is a phosphoenolpyruvate carboxykinase (PEPCK) inhibitor. SKF-34288 hydrochloride is a potent hypoglycemic agent via inhibition of glucose synthesis through the specific inhibition of PEPCK in the gluconeogenesis pathway. SKF-34288 hydrochloride inhibits Asn metabolism and results in an increase in amino acids and amides.
  • HY-144035
    GLP-1R agonist 4

    GCGR Cancer
    GLP-1R agonist 4 is a potent agonist of GLP-1R. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 4 has the potential for the research of diabetes (extracted from patent WO2019239319A1, compound 96).
  • HY-144717
    PTP1B-IN-18

    Phosphatase Metabolic Disease
    PTP1B-IN-18 is an orally active complete mixed type protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 35.2 μM. PTP1B-IN-18 can be used for type 2 diabetes research.
  • HY-144034
    GLP-1R agonist 3

    GCGR Metabolic Disease
    GLP-1R agonist 3 is a potent agonist of GLP-1R. GLP-1R agonist 3 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 3 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 1).
  • HY-144033
    GLP-1R agonist 1

    GCGR Metabolic Disease
    GLP-1R agonist 1 is a potent agonist of GLP-1R. GLP-1R agonist 1 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 1 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 4).
  • HY-147246
    Berberine ursodeoxycholate

    HTD1801; BUDCA

    Others Metabolic Disease
    Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes.
  • HY-144718
    PTP1B-IN-17

    Phosphatase Metabolic Disease
    PTP1B-IN-17 (Compound 45), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 30.2 μM. PTP1B-IN-17 can be used for the research of type 2 diabetes.
  • HY-144716
    PTP1B-IN-19

    Phosphatase Metabolic Disease
    PTP1B-IN-19 (Compound 43), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 23.3 μM. PTP1B-IN-19 can be used for the research of type 2 diabetes.
  • HY-144713
    PTP1B-IN-16

    Phosphatase Metabolic Disease
    PTP1B-IN-16 (Compound 46), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 12.6 μM. PTP1B-IN-16 can be used for the research of type 2 diabetes.